Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Adult Solid Neoplasm|Estrogen Receptor Negative|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: DRUG: Cilengitide|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|OTHER: Pharmacological Study
Sponsor: National Cancer Institute (NCI)